Welcome to our dedicated page for MNK news (Ticker: MNK), a resource for investors and traders seeking the latest updates and insights on MNK stock.
Keenova Therapeutics plc reports company news around its branded therapeutics portfolio for rare and unaddressed conditions. Recurring updates cover financial results, clinical publications, disease-awareness campaigns, and presentations involving products and programs such as Acthar Gel, XIAFLEX, TERLIVAZ, and collagenase clostridium histolyticum research.
The company's communications emphasize specialty therapeutic areas that include rheumatology, ophthalmology, nephrology, neurology, pulmonology, orthopedics, urology, and neonatal respiratory critical care. News also covers integration activity following its business combination, U.S. manufacturing operations, and portfolio performance drivers across established branded medicines.
Keenova Therapeutics (NYSE:MNK) announced publication of a new manuscript on Acthar Gel (repository corticotropin injection) in the peer-reviewed Journal of Comparative Effectiveness Research. The Keenova-sponsored, retrospective, physician-reported, survey-based chart review analyzed real-world clinical data from patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and dermatomyositis/polymyositis (DM/PM) treated with Acthar Gel.
The study evaluated patient characteristics, treatment patterns, and physicians’ assessments of outcomes in complex, often treatment-refractory cases. According to Keenova, these findings expand available evidence on how Acthar Gel is used as a treatment option for appropriate, eligible patients who have not responded to prior therapies.
Keenova Therapeutics (NYSE:MNK) reported positive Phase 3 results for XIAFLEX in treating plantar fibromatosis. The pivotal trial met its primary endpoint, showing statistically significant and clinically meaningful pain reduction versus placebo on the NRS scale, and achieved key ranked secondary endpoints on the FFI.
Additional secondary measures, including FFI pain subscale, global improvement and disease severity, treatment satisfaction, and nodule characteristics, also improved significantly. The safety profile matched known XIAFLEX data, with mostly mild to moderate adverse events and no treatment-related serious events. Keenova plans an FDA submission in Q4 2026 and targets a 2028 launch.
Keenova (NYSE:MNK) launched a Men's Health Month initiative focused on education and outreach about men's physical, mental, and sexual health, including Peyronie's disease.
Key elements include a Reddit AMA on June 18, a new Men's Sexual Health Screener for providers, targeted digital campaigns, new online content, and support for Wear Blue Day.
Keenova Therapeutics (MNK) announced new final updated data from a dedicated ventral curvature analysis of Peyronie's disease treated with XIAFLEX (collagenase clostridium histolyticum). Results to be presented at the American Urological Association 2026 meeting indicate clinical effectiveness and safety in ventral curvature consistent with other Peyronie's disease presentations.
Keenova Therapeutics (MNK) reported first-quarter 2026 net sales from continuing operations of $468 million, driven by Acthar Gel net sales of $170 million (up 47% YoY) and XIAFLEX net sales of $134 million.
The company posted a loss from continuing operations of $114 million, reflecting non-cash fair value adjustments and Endo-related costs, while adjusted EBITDA reached $174 million. Keenova realized $23 million of merger synergies, remains on track for $100 million in 2026, and reaffirmed 2026 net sales guidance of $1.94–$2.00 billion and adjusted EBITDA of $730–$760 million. XIAFLEX clinical milestones and an NYSE listing pursuit in H2 2026 also remain on track.
Keenova Therapeutics (NASDAQ:MNK) on May 4, 2026 launched a national consumer and disease awareness campaign, Don't Be a Viking, focused on Dupuytren's contracture.
The campaign features 30- and 15-second TV spots, streaming and digital placements, and directs people to FindaHandSpecialist.com to connect with hand specialists and learn about nonsurgical treatment options.
Keenova (NASDAQ:MNK) will present new clinical analysis of TERLIVAZ® (terlipressin) at Digestive Disease Week, May 2-5, 2026. The presentation reports preliminary real-world treatment patterns and outcomes for hepatorenal syndrome-acute kidney injury (HRS-AKI) from seven U.S. hospitals and aims to inform clinical practice.
Keenova Therapeutics (NASDAQ:MNK) will report its first quarter 2026 financial results on May 12, 2026 before market open and will host a conference call the same day.
The live call is scheduled for 8:00 a.m. ET, with an audio webcast accessible via the Investor Relations site and a replay available after the event.
Keenova (NYSE:MNK) reported robust Q4 2025 results with net sales from continuing operations of $543.0M, driven by Acthar Gel $205.6M (+48%) and XIAFLEX $156.5M. Adjusted EBITDA from continuing operations was $210M–$220M and loss from continuing operations was $(105.0M)–(115.0M).
The company provided 2026 guidance of $1.94B–$2.00B net sales and $730M–$760M Adjusted EBITDA, and expects ~ $100M pre-tax merger synergies in 2026 toward a $150M run-rate.
Keenova Therapeutics (NYSE:MNK) will present new clinical analysis of TERLIVAZ (terlipressin) at the Society of Hospital Medicine Converge, March 29–April 1, 2026.
The presentation reports real-world utilization patterns and outcomes in hospitalized U.S. adults with hepatorenal syndrome‑acute kidney injury (HRS‑AKI). According to the company, TERLIVAZ is the first and only FDA‑approved therapy to improve kidney function in adults with HRS‑AKI. The study is a retrospective cohort authored by A. Sidney Barritt IV and colleagues.